The COVID-19 Antivirals and Therapeutics Taskforce
The DHSC-led COVID-19 Antivirals and Therapeutics Taskforce co-ordinates the end-to-end provision of treatments for coronavirus (COVID-19) in the UK so patients get access to safe and effective treatments as soon as possible.
The COVID-19 Antivirals and Therapeutics Taskforce
The COVID-19 Antivirals and Therapeutics Taskforce is responsible for the end-to-end provision of treatments for coronavirus (COVID-19) in the UK.
The taskforce is responsible for:
- identifying potential COVID-19 therapeutics
- trialling these as part of an advanced programme of clinical trials
- deploying effective treatments to UK patients
The taskforce works with industry experts to identify, develop and procure novel oral antivirals (those in pill or tablet form) that patients can take promptly following infection.
Contact details
Email: attf@dhsc.gov.uk
For Freedomfreedom of Informationinformation requests, please contact DHSC.
Further information
Access to community treatments
Clinical trials
Protection
The Antivirals and Therapeutics Taskforce has worked with key stakeholders to explore new and improved methods of treatingpreventing COVID-19.COVID-19, including funding research.
ThisPROTECT-V includesis a phase 3 trial testing prophylactic treatments,interventions whichfor canCOVID-19 in vulnerable renal and immunocompromised patients.
Prophylactic medicines may be administered as a preventative treatment to help reduce the spreadrisk of severe COVID-19 disease among the most vulnerable groups.
The ‘Evaluation of preventative medicines’, linked to below, gives information on clinical deployment decisions on preventative medicines.
Last updated
-
Added information under 'Protection' including a link to the Evusheld evaluation.
-
Added new 'Protection' section containing links to pages on the RAPID C-19 Oversight Group report into Evusheld and letter to patient groups on the decision not to procure Evusheld.
-
First published.